Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Int J Mol Sci
2022 Dec 13;2324:. doi: 10.3390/ijms232415852.
Show Gene links
Show Anatomy links
Identification of New Purpuroine Analogues from the Arctic Echinodermata Pteraster militaris That Inhibit FLT3-ITD+ AML Cell Lines.
Ullsten S
,
Petit GA
,
Isaksson J
,
Hansen IKØ
,
Schneider YK
,
Jenssen M
,
Li C
,
Hansen KØ
.
???displayArticle.abstract???
Isolation of bioactive products from the marine environment is considered a very promising approach to identify new compounds that can be used for further drug development. In this work we have isolated three new compounds from the purpuroine family by mass-guided preparative HPLC; purpuroine K-M. These compounds where screened for antibacterial- and antifungal activity, antibiofilm formation and anti-cell proliferation activity. Additionally, apoptosis-, cell cycle-, kinase binding- and docking studies were performed to evaluate the mechanism-of-action. None of the compounds showed activity in antibacterial-, antibiofilm- or antifungal assays. However, one of the isolated compounds, purpuroine K, showed activity against two cell lines, MV-4-11 and MOLM-13, two AML cell lines both carrying the FTL3-ITD mutation. In MV-4-11 cells, purpuroine K was found to increase apoptosis and arrest cells cycle in G1/G0, which is a common feature of FLT3 inhibitors. Interactions between purpuroine K and the FLT3 wild type or FLT3 ITD mutant proteins could however not be elucidated in our kinase binding and docking studies. In conclusion, we have isolated three novel molecules, purpuroine K-M, one of which (purpuroine K) shows a potent activity against FLT3-ITD mutated AML cell lines, however, the molecular target(s) of purpuroine K still need to be further investigated.
Bailon-Moscoso,
Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.
2017, Pubmed
Bailon-Moscoso,
Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.
2017,
Pubmed
Blunt,
Marine natural products.
2018,
Pubmed
Carney,
A new bastadin from the sponge Psammaplysilla purpurea.
1993,
Pubmed
Eriksson,
AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
2014,
Pubmed
Friesner,
Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.
2006,
Pubmed
Friesner,
Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.
2004,
Pubmed
Galeano,
Antiparasitic bromotyrosine derivatives from the marine sponge Verongula rigida.
2011,
Pubmed
Grafone,
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.
2012,
Pubmed
Greenwood,
Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution.
2010,
Pubmed
Griffith,
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.
2004,
Pubmed
Gu,
Use of natural products as chemical library for drug discovery and network pharmacology.
2013,
Pubmed
Guo,
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells.
2012,
Pubmed
Halgren,
Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.
2004,
Pubmed
Hu,
Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012.
2015,
Pubmed
Jacobson,
A hierarchical approach to all-atom protein loop prediction.
2004,
Pubmed
Kawase,
Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.
2019,
Pubmed
Kazi,
FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications.
2019,
Pubmed
Kennedy,
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.
2020,
Pubmed
Kiyoi,
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
2020,
Pubmed
Lagunas-Rangel,
FLT3-ITD and its current role in acute myeloid leukaemia.
2017,
Pubmed
Mah,
Global diversity and phylogeny of the Asteroidea (Echinodermata).
2012,
Pubmed
,
Echinobase
Meshinchi,
Structural and functional alterations of FLT3 in acute myeloid leukemia.
2009,
Pubmed
Newman,
Natural Products as Sources of New Drugs from 1981 to 2014.
2016,
Pubmed
Pettersen,
UCSF ChimeraX: Structure visualization for researchers, educators, and developers.
2021,
Pubmed
Sastry,
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments.
2013,
Pubmed
Sexauer,
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
2012,
Pubmed
Shelley,
Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules.
2007,
Pubmed
Shen,
Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases.
2012,
Pubmed
Stirewalt,
The role of FLT3 in haematopoietic malignancies.
2003,
Pubmed
Tsuda,
Nakirodin A, a bromotyrosine alkaloid from a Verongid sponge.
2002,
Pubmed
Verstraete,
Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex.
2011,
Pubmed
Wang,
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
2007,
Pubmed
Wu,
FLT3 inhibitors in acute myeloid leukemia.
2018,
Pubmed
Zhu,
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
2021,
Pubmed
